{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:25:01Z","timestamp":1791509101362,"version":"4.3.4"},"reference-count":182,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sarcoidosis is a multiorgan, granulomatous disease of an unknown etiology. The characteristic feature of the disease is the formation of noncaseating granulomas. Spontaneous resolution occurs in most patients, but the clinical course may be chronic or progressive, complicated by pulmonary fibrosis, which is a major cause of mortality in sarcoidosis. Recent studies have provided new information on the immunological mechanisms of pulmonary fibrosis. Its pathogenesis includes the alteration of lymphocyte activity and the imbalance between their subpopulations, the polarization of macrophages to the profibrotic phenotype, and an imbalance between the activity of metalloproteinases and their tissue inhibitors. A multidisciplinary approach is required for the optimal management of fibrotic pulmonary sarcoidosis. Clinical symptoms, serum biomarkers, imaging, pulmonary function test results, other organ involvement, comorbidities, and complications should be considered when assessing disease activity and selecting the most appropriate treatment. The use of anti-inflammatory drugs is often discussed. There has been no consensus reached on whether antifibrotic agents should be added or used in monotherapy as initial treatment in such cases. This article will review all the information on fibrotic pulmonary sarcoidosis and present factors associated with fibrosis development, prognosis, and treatment options.<\/jats:p>","DOI":"10.3390\/jcm14072381","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:50:16Z","timestamp":1743389416000},"page":"2381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fibrotic Pulmonary Sarcoidosis\u2014From Pathogenesis to Management"],"prefix":"10.3390","volume":"14","author":[{"given":"Ewa","family":"\u0141y\u017cwa","sequence":"first","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wakuli\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szturmowicz","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Tomkowski","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9311-9753","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Sobiecka","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","first-page":"362","article-title":"Pulmonary Fibrosis in Sarcoidosis","volume":"10","author":"Patterson","year":"2013","journal-title":"Clin. Features Outcomes Ann. ATS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/hmg\/ddq325","article-title":"Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups","volume":"19","author":"Sato","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Calender, A., Weichhart, T., Valeyre, D., and Pacheco, Y. (2020). Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082633"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis Based on Health Care Use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1183\/13993003.00477-2016","article-title":"Sarcoidosis incidence and prevalence: A nationwide register-based assessment in Sweden","volume":"48","author":"Arkema","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Begh\u00e8, D., Dall\u2019Asta, L., Garavelli, C., Pastorelli, A.A., Muscarella, M., Saccani, G., and Bertorelli, G. (2017). Sarcoidosis in an Italian province. Prevalence and environmental risk factors. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176859"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1800385","DOI":"10.1183\/13993003.00385-2018","article-title":"Familial aggregation and heritability of sarcoidosis: A Swedish nested case\u2212control study","volume":"52","author":"Rossides","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/thx.39.1.14","article-title":"High prevalence of familial sarcoidosis in an Irish population","volume":"39","author":"Brennan","year":"1984","journal-title":"Thorax"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/aje\/153.2.188","article-title":"Familial risk ratio of sarcoidosis in African-American sibs and parents","volume":"153","author":"Rybicki","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1098-2272(1996)13:1<23::AID-GEPI3>3.0.CO;2-7","article-title":"Heterogeneity of familial risk in sarcoidosis","volume":"13","author":"Rybicki","year":"1996","journal-title":"Genet. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/thorax.55.9.751","article-title":"Epidemiology of familial sarcoidosis in the UK","volume":"55","author":"McGrath","year":"2000","journal-title":"Thorax"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"015","DOI":"10.1055\/s-2007-970330","article-title":"Genetics of Sarcoidosis","volume":"28","author":"Iannuzzi","year":"2007","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/crj.12559","article-title":"Associations between sarcoidosis clinical course and ANXA11 rs1049550 C\/T, BTNL2 rs2076530 G\/A, and HLA class I and II alleles","volume":"12","author":"Morais","year":"2018","journal-title":"Clin. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/tan.12326","article-title":"HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis","volume":"83","author":"Darlington","year":"2014","journal-title":"Tissue Antigens"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-0039.2010.01590.x","article-title":"Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis","volume":"77","author":"Heron","year":"2011","journal-title":"Tissue Antigens"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/gene.2012.48","article-title":"Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans","volume":"14","author":"Levin","year":"2013","journal-title":"Genes. Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.129.6.1584","article-title":"Transforming Growth Factor-\u03b2 Gene Polymorphisms in Sarcoidosis Patients With and Without Fibrosis","volume":"129","author":"Kruit","year":"2006","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/qjmed\/hcx243","article-title":"Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis","volume":"111","author":"Cooke","year":"2018","journal-title":"QJM Int. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1164\/rccm.201304-0760OC","article-title":"The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis","volume":"188","author":"Armstrong","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/thoraxjnl-2012-201786","article-title":"Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis","volume":"68","author":"Stock","year":"2013","journal-title":"Thorax"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/03009730802579729","article-title":"BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity","volume":"114","author":"Danila","year":"2009","journal-title":"Upsala J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2478\/v10039-008-0014-z","article-title":"BAL fluid cells and pulmonary function in different radiographic stages of newly diagnosed sarcoidosi","volume":"53","author":"Danila","year":"2008","journal-title":"Adv. Med. Sci."},{"key":"ref_23","first-page":"98","article-title":"Type 2 macrophages and Th2 CD4+ cells in interstitial lung diseases (ILDs): An overview","volume":"35","year":"2018","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Barros, M.H.M., Hauck, F., Dreyer, J.H., Kempkes, B., and Niedobitek, G. (2013). Macrophage polarisation: An immunohistochemical approach for identifying M1 and M2 macrophages. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080908"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1172\/JCI111852","article-title":"Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis","volume":"75","author":"Robinson","year":"1985","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1802153","DOI":"10.1183\/13993003.021532018","article-title":"Moving target: Shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder","volume":"54","author":"Kaiser","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_27","first-page":"1","article-title":"Detection of lymphokines and lymphokine receptors in pulmonary sarcoidosis. Immunohistologic evidence that inflammatory macrophages express IL-2 receptors","volume":"123","author":"Hancock","year":"1986","journal-title":"Am. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor \u03b21","volume":"194","author":"Lee","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/jrms.JRMS_74_19","article-title":"The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients","volume":"25","author":"Abedini","year":"2020","journal-title":"J. Res. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thorax.58.6.519","article-title":"Increased interleukin-13 expression in patients with sarcoidosis","volume":"58","author":"Hauber","year":"2003","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","article-title":"Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis","volume":"51","author":"Berge","year":"2012","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cyto.2012.12.016","article-title":"Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease","volume":"61","author":"Patterson","year":"2013","journal-title":"Cytokine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ftw068","DOI":"10.1093\/femspd\/ftw068","article-title":"Macrophage form, function, and phenotype in mycobacterial infection: Lessons from tuberculosis and other diseases","volume":"74","author":"McClean","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","article-title":"Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis","volume":"179","author":"Prasse","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-11-121","article-title":"No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis","volume":"11","author":"Idali","year":"2010","journal-title":"Respir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humimm.2017.10.009","article-title":"Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity","volume":"79","author":"Shamaei","year":"2018","journal-title":"Hum. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5114\/ceji.2016.60990","article-title":"Macrophage polarization in interstitial lung diseases","volume":"41","author":"Wojtan","year":"2016","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., and Guggino, G. (2021). Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637829"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/eji.201040539","article-title":"IFN-\u03b3 and IL-12 synergize to convert in vivo generated Th17 into Th1\/Th17 cells","volume":"40","author":"Lexberg","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1183\/13993003.00092-2016","article-title":"Expanded lung T-bet+ ROR\u03b3T+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype","volume":"48","author":"Kaiser","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1701124","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes","volume":"51","author":"Broos","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/15353702231182224","article-title":"Interleukin-17A plays a key role in pulmonary fibrosis following Propionibacterium acnes \u2013induced sarcoidosis-like inflammation","volume":"248","author":"Jiang","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, H., Jiang, D., Zhu, L., Zhou, G., Xie, B., Cui, Y., Costabel, U., and Dai, H. (2023). Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and BALF of sarcoidosis patients: Relationship to disease activity and the fibrotic radiographic phenotype. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1185443"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-015-0265-8","article-title":"Impaired survival of regulatory T cells in pulmonary sarcoidosis","volume":"16","author":"Broos","year":"2015","journal-title":"Respir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2011.03.015","article-title":"Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation","volume":"140","author":"Rappl","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1202891","article-title":"Reversal of Global CD4+ Subset Dysfunction Is Associated with Spontaneous Clinical Resolution of Pulmonary Sarcoidosis","volume":"190","author":"Richmond","year":"2013","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ccm.2023.08.011","article-title":"Fibrotic Pulmonary Sarcoidosis","volume":"45","author":"Nunes","year":"2024","journal-title":"Clin. Chest Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103107","DOI":"10.1016\/j.jaut.2023.103107","article-title":"Pulmonary sarcoidosis: A comprehensive review: Past to present","volume":"149","author":"Belperio","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: Comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/ar2192","article-title":"Pulmonary hypertension associated with sarcoidosis","volume":"9","author":"Baughman","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","article-title":"Distinctive Clinical, Radiographic, and Functional Characteristics of Patients With Sarcoidosis-Related Pulmonary Hypertension","volume":"128","author":"Sulica","year":"2005","journal-title":"Chest"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00408-011-9280-9","article-title":"Aspergillus Lung Disease in Patients with Sarcoidosis: A Case Series and Review of the Literature","volume":"189","author":"Pena","year":"2011","journal-title":"Lung"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1602396","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Uzunhan","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5603\/PiAP.2016.0030","article-title":"Fatigue Syndrome in Sarcoidosis","volume":"84","author":"Piotrowski","year":"2016","journal-title":"Adv. Respir. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5603\/PiAP.2015.0002","article-title":"Fatigue in Patients with Inactive Sarcoidosis Does Not Correlate with Lung Ventilation Ability or Walking Distance","volume":"83","author":"Ziora","year":"2015","journal-title":"Pilot. Study. Adv. Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1378\/chest.08-2569","article-title":"Airway Involvement in Sarcoidosis","volume":"136","author":"Polychronopoulos","year":"2009","journal-title":"Chest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of Intrathoracic Sarcoidosis in England","volume":"2","author":"Scadding","year":"1961","journal-title":"BMJ"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1800050","DOI":"10.1183\/13993003.00050-2018","article-title":"It\u2019s time to evolve from Scadding: Phenotyping sarcoidosis","volume":"51","author":"Culver","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Du, S.S., Zhao, M.M., Li, Q.H., Zhou, Y., Song, J.C., and Li, H. (2022). Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01942-y"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of Mortality in Pulmonary Sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106059","DOI":"10.1016\/j.rmed.2020.106059","article-title":"Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?","volume":"170","author":"Kirkil","year":"2020","journal-title":"Respir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: A case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.chest.2023.10.021","article-title":"High-Resolution CT Scan Fibrotic Patterns in Stage IV Pulmonary Sarcoidosis","volume":"165","author":"Obi","year":"2024","journal-title":"CHEST"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bailey, G.L., Wells, A.U., and Desai, S.R. (2024). Imaging of Pulmonary Sarcoidosis\u2014A Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030822"},{"key":"ref_68","first-page":"560","article-title":"The role of chest X-ray in the early diagnosis and staging of sarcoidosis: Is it really should be done?","volume":"19","author":"Koc","year":"2023","journal-title":"Reumatol. Cl\u00ednica (Engl. Ed.)"},{"key":"ref_69","first-page":"65","article-title":"Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography","volume":"14","author":"Oberstein","year":"1997","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17476348.2023.2183193","article-title":"An expert overview of pulmonary fibrosis in sarcoidosis","volume":"17","author":"Gupta","year":"2023","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_72","unstructured":"Wakulinski, J. (2018). Typical and Atypical Radiological Manifestations of Thoracic Sarcoidosis with Their Pathologic Correlation, European Congress of Radiology-ECR."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2214\/ajr.174.6.1741751","article-title":"Sarcoidosis with Pulmonary Fibrosis: CT Patterns and Correlation with Pulmonary Function","volume":"174","author":"Abehsera","year":"2000","journal-title":"Am. J. Roentgenol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1148\/rg.306105512","article-title":"Pulmonary Sarcoidosis: Typical and Atypical Manifestations at High-Resolution CT with Pathologic Correlation","volume":"30","author":"Criado","year":"2010","journal-title":"RadioGraphics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-0037-1603765","article-title":"Imaging for Sarcoidosis","volume":"38","author":"Calandriello","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1378\/chest.75.6.663","article-title":"Bronchostenosis due to Sarcoidosis","volume":"75","author":"Olsson","year":"1979","journal-title":"Chest"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.chest.2021.01.003","article-title":"Distinct Airway Involvement in Subtypes of End-Stage Fibrotic Pulmonary Sarcoidosis","volume":"160","author":"Verleden","year":"2021","journal-title":"Chest"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000893","article-title":"Novel insights in fibrotic pulmonary sarcoidosis","volume":"28","author":"Comes","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_79","first-page":"S466","article-title":"Pneumothorax in sarcoidosis","volume":"6","author":"Manika","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Papiris, S.A., Kolilekas, L., Rivera, N., Spanos, M., Li, G., Gokulnath, P., Chatterjee, E., Georgakopoulos, A., Kallieri, M., and Papaioannou, A.I. (2023). From Karl Wurm and Guy Scadding\u2019s staging to 18F-FDG PET\/CT scan phenotyping and far beyond: Perspective in the evading history of phenotyping in sarcoidosis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1174518"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/MCP.0b013e328363ed0d","article-title":"The role of the PET scan in the management of sarcoidosis","volume":"19","author":"Mostard","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"623036","DOI":"10.1155\/2013\/623036","article-title":"The Use of 18 F-FDG-PET\/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases","volume":"2013","author":"Glaudemans","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1148\/rg.2018180053","article-title":"PET\/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations","volume":"38","author":"Akaike","year":"2018","journal-title":"RadioGraphics"},{"key":"ref_84","first-page":"e2022018","article-title":"Imaging findings of fibrosis in pulmonary sarcoidosis","volume":"39","author":"Sawahata","year":"2022","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-022-02094-7","article-title":"Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis","volume":"23","author":"Schimmelpennink","year":"2022","journal-title":"Respir. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.21037\/jtd.2016.06.39","article-title":"Oxygen desaturation during a 6-minute walk test as a predictor of maximal exercise-induced gas exchange abnormalities in sarcoidosis","volume":"8","author":"Chenivesse","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_87","first-page":"e2022011","article-title":"Pirfenidone for Fibrotic Sarcoidosis (PIRFS): Results of a Double Blind Placebo Controlled Feasibility Study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed Ventilatory Defects in Pulmonary Sarcoidosis","volume":"158","author":"Kouranos","year":"2020","journal-title":"Chest"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/1817-1737.49414","article-title":"The six-minute walk test in patients with pulmonary sarcoidosis","volume":"4","author":"Alhamad","year":"2009","journal-title":"Ann. Thorac. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.202204-328OC","article-title":"Heterogeneity of Lung Function Phenotypes in Sarcoidosis: Role of Race and Sex Differences","volume":"20","author":"Sharp","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"230085","DOI":"10.1183\/16000617.0085-2023","article-title":"Sarcoidosis-associated pulmonary fibrosis: Joining the dots","volume":"32","author":"Bandyopadhyay","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"B\u0105czek, K., and Piotrowski, W.J. (2024). Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1445923"},{"key":"ref_96","first-page":"185","article-title":"Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients","volume":"36","author":"Kiani","year":"2019","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1183\/09031936.00175907","article-title":"Clinical predictors of pulmonary hypertension in sarcoidosis","volume":"32","author":"Bourbonnais","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"106801","DOI":"10.1016\/j.rmed.2022.106801","article-title":"The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry","volume":"196","author":"Gupta","year":"2022","journal-title":"Respir. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.rmed.2006.02.004","article-title":"The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis","volume":"100","author":"Lettieri","year":"2006","journal-title":"Respir. Med."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Alhamad, E.H., Shaik, S.A., Idrees, M.M., Alanezi, M.O., and Isnani, A.C. (2010). Outcome measures of the 6 minute walk test: Relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm. Med., 10.","DOI":"10.1186\/1471-2466-10-42"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1183\/09031936.04.00101303","article-title":"Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases","volume":"24","author":"Welker","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.21037\/jtd.2017.01.17","article-title":"Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis","volume":"9","author":"Gruslys","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1183\/09031936.99.13613459","article-title":"Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis?","volume":"13","author":"Drent","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Feng, H., Yan, L., Zhao, Y., Li, Z., and Kang, J. (2022). Neutrophils in Bronchoalveolar Lavage Fluid Indicating the Severity and Relapse of Pulmonary Sarcoidosis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.787681"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.rmed.2010.09.007","article-title":"The impact of gas exchange measurement during exercise in pulmonary sarcoidosis","volume":"105","author":"Kollert","year":"2011","journal-title":"Respir. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1183\/09031936.03.00010403","article-title":"Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis","volume":"21","author":"Ziegenhagen","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2003468","DOI":"10.1183\/13993003.03468-2020","article-title":"Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome","volume":"58","author":"Lepzien","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000345386","article-title":"Sarcoidal Granulomas in Cytological Specimens from Intrathoracic Adenopathy: Morphologic Characteristics and Radiographic Correlations","volume":"85","author":"Cancellieri","year":"2013","journal-title":"Respiration"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Tana, C., Donatiello, I., Caputo, A., Tana, M., Naccarelli, T., Mantini, C., and Giamberardino, M.A. (2021). Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis. Cells, 11.","DOI":"10.3390\/cells11010059"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jcp.30.5.395","article-title":"Sarcoidosis: Histopathological definition and clinical diagnosis","volume":"30","author":"Mitchell","year":"1977","journal-title":"J. Clin. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1378\/chest.94.1.193","article-title":"Diffuse Interstitial Pneumonitis and Fibrosis in Sarcoidosis","volume":"94","author":"Aisner","year":"1988","journal-title":"Chest"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1183\/09031936.00150609","article-title":"Chronic interstitial pneumonitis in end-stage sarcoidosis","volume":"35","author":"Shigemitsu","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Cuccinelli, E., Bernardinello, N., Castelli, G., Petrarulo, S., Bellani, S., Saetta, M., Spagnolo, P., and Balestro, E. (2023). Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1855.v1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2169\/internalmedicine.51.7394","article-title":"A Case of Combined Sarcoidosis and Usual Interstitial Pneumonia","volume":"51","author":"Tachibana","year":"2012","journal-title":"Intern. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PAS.0b013e3182785a2d","article-title":"End-stage Sarcoid Lung Disease Is Distinct from Usual Interstitial Pneumonia","volume":"37","author":"Xu","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kamp, J.C., Neubert, L., Stark, H., Hinrichs, J.B., Boekhoff, C., Seidel, A.D., Ius, F., Haverich, A., Gottlieb, J., and Welte, T. (2022). Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis. Cells, 11.","DOI":"10.3390\/cells11040664"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of Explanted Lungs From Patients With a Diagnosis of Pulmonary Sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2169\/internalmedicine.45.1385","article-title":"Pulmonary Sarcoidosis with Usual Interstitial Pneumonia Distributed Predominantly in the Lower Lung Fields","volume":"45","author":"Nobata","year":"2006","journal-title":"Intern. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2018.08.008","article-title":"Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?","volume":"144","author":"Collins","year":"2018","journal-title":"Respir. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000274492","article-title":"Massive Hemoptysis: An Update on the Role of Bronchoscopy in Diagnosis and Management","volume":"80","author":"Sakr","year":"2010","journal-title":"Respiration"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/thx.2005.042838","article-title":"Pulmonary hypertension associated with sarcoidosis: Mechanisms, haemodynamics and prognosis","volume":"61","author":"Nunes","year":"2005","journal-title":"Thorax"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: Results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Parikh, K.S., Dahhan, T., Nicholl, L., Ruopp, N., Pomann, G.M., Fortin, T., and Rajagopal, S. (2019). Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-40030-w"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Sobiecka, M., Szturmowicz, M., Lewandowska, K., Kowalik, A., \u0141y\u017cwa, E., Zimna, K., Bara\u0144ska, I., Jakubowska, L., Ku\u015b, J., and Langfort, R. (2021). Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: A retrospective cohort study. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01794-y"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Kacprzak, A., Tomkowski, W., and Szturmowicz, M. (2023). Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension\u2014A Challenging Mystery. Diagnostics, 13.","DOI":"10.3390\/diagnostics13193132"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kim, D.S. (2022). Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Encyclopedia of Respiratory Medicine, Elsevier. Available online: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128012383114540.","DOI":"10.1016\/B978-0-12-801238-3.11454-0"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1378\/chest.12-1060","article-title":"Acute Pulmonary Exacerbations of Sarcoidosis","volume":"142","author":"Panselinas","year":"2012","journal-title":"Chest"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.rmed.2013.10.014","article-title":"Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients","volume":"107","author":"Baughman","year":"2013","journal-title":"Respir. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.chest.2024.06.3839","article-title":"Sarcoidosis and Emergency Hospitalization","volume":"167","author":"Gazengel","year":"2024","journal-title":"CHEST"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","article-title":"From granuloma to fibrosis: Sarcoidosis associated pulmonary fibrosis","volume":"22","author":"Bonham","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/jcm13010241","article-title":"Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis","volume":"13","author":"Kim","year":"2023","journal-title":"J. Clin. Med."},{"key":"ref_138","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2005","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: Integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_140","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_141","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5603\/PiAP.2014.0069","article-title":"Methotrexate as a Single Agent for Treating Pulmonary Sarcoidosis: A Single Centre Real-Life Prospective Study","volume":"82","author":"Bednarek","year":"2014","journal-title":"Adv. Respir. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_146","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000345596","article-title":"Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective Study","volume":"86","author":"Brill","year":"2013","journal-title":"Respiration"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_152","first-page":"46","article-title":"Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_153","first-page":"e2021035","article-title":"Roflumilast (Daliresp\u00ae) to reduce acute pulmonary events in fibrotic sarcoidosis: A multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: Pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1172\/JCI200420997","article-title":"Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis","volume":"114","author":"Phillips","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/cfr.2021.30","article-title":"Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond","volume":"8","author":"Aimo","year":"2022","journal-title":"Card. Fail. Rev."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary FibrosisAn Update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","article-title":"Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib","volume":"72","author":"Bellamri","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00508-024-02444-z","article-title":"Positionspapier der \u00d6GR und \u00d6GP zur Diagnose und Therapie der Sarkoidose 2024","volume":"136","author":"Sterniste","year":"2024","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000486964","article-title":"Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study","volume":"95","author":"Lingner","year":"2018","journal-title":"Respiration"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A Randomized Controlled Trial","volume":"38","author":"Naz","year":"2018","journal-title":"J. Cardiopulm. Rehabil. Prev."},{"key":"ref_169","first-page":"1","article-title":"Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial","volume":"77","author":"Wallaert","year":"2020","journal-title":"Respir. Med. Res."},{"key":"ref_170","first-page":"87","article-title":"Infection prevention in sarcoidosis: Proposal for vaccination and prophylactic therapy","volume":"37","author":"Syed","year":"2020","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir. Med."},{"key":"ref_172","first-page":"378","article-title":"Lung transplantation for pulmonary sarcoidosis","volume":"71","author":"Taimeh","year":"2016","journal-title":"Twenty-Five Years Exp. USA Thorax"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1378\/chest.120.3.873","article-title":"Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation","volume":"120","author":"Arcasoy","year":"2001","journal-title":"Chest"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1600-6143.2006.01276.x","article-title":"Development of the New Lung Allocation System in the United States","volume":"6","author":"Egan","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"106828","DOI":"10.1016\/j.rmed.2022.106828","article-title":"Trends in sarcoidosis mortality rate in Japan from 2001 to 2020: A population-based study","volume":"196","author":"Harada","year":"2022","journal-title":"Respir. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.rmed.2018.11.010","article-title":"Sarcoidosis deaths in the United States: 1999\u20132016","volume":"149","author":"Kearney","year":"2019","journal-title":"Respir. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related Mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MCP.0000000000000080","article-title":"Morbidity and mortality in sarcoidosis","volume":"20","author":"Gerke","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_179","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations","volume":"119","author":"Perry","year":"1995","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_180","first-page":"e2024042","article-title":"Echocardiographic evaluation of left ventricular mechanics in sarcoidosis patients without overt heart disease: A systematic review and meta-analysis","volume":"41","author":"Sonaglioni","year":"2024","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic Pulmonary Fibrosis: A Composite Physiologic Index Derived from Disease Extent Observed by Computed Tomography","volume":"167","author":"Wells","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:06:01Z","timestamp":1760029561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":182,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072381"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072381","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}